NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change -0.04
Percentage change -2.96	%

Peers: TMO DHR A ILMN BIO QGEN TECH TWST PACB DNA

| Held by: IWM VTI VXF ARKG IWN IBB SCHA VTWO IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-0.36	Insider Own	3.18%	Shs Outstand	379.09M	Perf Week	10.08%
Market Cap	497.57M	Forward P/E	-	EPS next Y	-0.15	Insider Trans	65.11%	Shs Float	367.76M	Perf Month	21.30%
Enterprise Value	271.04M	PEG	-	EPS next Q	-0.07	Inst Own	72.28%	Short Float	4.39%	Perf Quarter	22.43%
Income	-132.76M	P/S	2.93	EPS this Y	55.47%	Inst Trans	-0.28%	Short Ratio	9.27	Perf Half Y	-25.14%
Sales	169.69M	P/B	1.09	EPS next Y	37.16%	ROA	-19.56%	Short Interest	16.16M	Perf YTD	-25.14%
Book/sh	1.20	P/C	1.93	EPS next 5Y	66.44%	ROE	-25.73%	52W High	2.41 -45.64%	Perf Year	-25.99%
Cash/sh	0.68	P/FCF	-	EPS past 3/5Y	12.51% 11.61%	ROIC	-27.67%	52W Low	0.92 42.39%	Perf 3Y	-18.63%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	10.13% 8.27%	Gross Margin	45.96%	Volatility	8.96% 8.61%	Perf 5Y	-68.05%
Dividend TTM	-	EV/Sales	1.60	EPS Y/Y TTM	64.34%	Oper. Margin	-74.44%	ATR (14)	0.10	Perf 10Y	-94.84%
Dividend Ex-Date	-	Quick Ratio	5.37	Sales Y/Y TTM	33.86%	Profit Margin	-78.24%	RSI (14)	60.73	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	6.12	EPS Q/Q	74.12%	SMA20	12.25%	Beta	1.31	Target Price	2.38
Payout	-	Debt/Eq	0.07	Sales Q/Q	-10.42%	SMA50	17.37%	Rel Volume	0.54	Prev Close	1.35
Employees	818	LT Debt/Eq	0.06	Earnings	May 06 AMC	SMA200	-11.79%	Avg Volume	1.74M	Price	1.31
IPO	Feb 10, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	-27.27% 1.73%	Trades		Volume	714,213	Change	-2.96%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-27-25	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Apr-16-24	Initiated	TD Cowen	Buy	$3.50
Apr-04-24	Initiated	Jefferies	Buy	$3.25
Jul-12-23	Initiated	KeyBanc Capital Markets	Overweight	$4

Jun-26-25 08:07AM	Illumina Stock May Benefit From New Agreement to Acquire SomaLogic (Zacks)
Jun-25-25 12:16AM	Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy (PR Newswire)
Jun-23-25 07:13AM	Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy (PR Newswire) +17.14%
07:05AM	Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina (GlobeNewswire)
06:58AM	Illumina to buy SomaLogic for up to $425M (MedTech Dive)
07:00AM	Loading…
May-30-25 07:00AM	Standard BioTools to Host Inaugural "Proteomics Roundtable" Webcast Series (GlobeNewswire)
May-09-25 05:00PM	Labrador Gold Announces Resignation of Director Kai Hoffmann (GlobeNewswire) +8.41%
May-07-25 08:26AM	Q1 2025 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
03:20AM	Standard BioTools Inc (LAB) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-06-25 05:15PM	Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.83%
04:01PM	Standard BioTools Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-05-25 10:10AM	Standard BioTools Inc (LAB) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Apr-24-25 07:00AM	Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025 (GlobeNewswire)
Apr-22-25 04:05PM	Sight Sciences Appoints Gary Burbach to its Board of Directors (GlobeNewswire) +6.72%
07:00AM	Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025 (GlobeNewswire)
04:01PM	Loading…
Feb-27-25 04:01PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire) -10.68%
07:09AM	Q4 2024 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
02:22AM	Standard BioTools Inc (LAB) Q4 2024 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
Feb-26-25 06:52PM	Standard BioTools: Q4 Earnings Snapshot (Associated Press Finance) -7.14%
04:01PM	Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 10:54AM	Standard BioTools Inc (LAB) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com) -5.26%
Feb-12-25 07:00AM	Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025 (GlobeNewswire)
Jan-13-25 07:00AM	Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue (GlobeNewswire) +26.38%
Jan-08-25 07:00AM	Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine (GlobeNewswire)
Dec-19-24 08:00AM	Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-07-24 08:00AM	Standard BioTools Appoints Alex Kim as Chief Financial Officer (GlobeNewswire)
Oct-31-24 11:00AM	Standard BioTools Inc (LAB) Q3 2024 Earnings Call Highlights: Navigating Market Challenges with ... (GuruFocus.com)
08:01AM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-30-24 05:20PM	Standard BioTools (LAB) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +7.43%
04:15PM	Standard BioTools: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Loading…
04:01PM	Standard BioTools Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-21-24 09:03PM	Millennium Management LLC Acquires Shares in Standard BioTools Inc (GuruFocus.com)
Oct-16-24 08:00AM	Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024 (GlobeNewswire)
Oct-03-24 04:56AM	Is Standard BioTools Inc. (LAB) the Best NASDAQ Stock Under $5? (Insider Monkey)
Sep-24-24 08:00AM	Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan 11K Platform (GlobeNewswire) +5.35%
Sep-18-24 08:00AM	Standard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH) (GlobeNewswire)
Aug-26-24 08:00AM	Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-23-24 06:03PM	Appian, Bitfarms, Standard BioTools, and More Stocks See Action From Activist Investors (Barrons.com) +9.74%
Aug-06-24 04:01PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-01-24 09:14AM	Q2 2024 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) -36.61%
Jul-31-24 09:57PM	LAB Stock Earnings: Standard BioTools Reported Results for Q2 2024 (InvestorPlace)
05:40PM	Standard BioTools (LAB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:36PM	Standard BioTools: Q2 Earnings Snapshot (Associated Press Finance)
04:02PM	Standard BioTools Announces Senior Leadership Changes (GlobeNewswire)
04:01PM	Standard BioTools Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-17-24 08:01AM	Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024 (GlobeNewswire)
May-28-24 04:01PM	Standard BioTools Purchases the Carterra LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers (GlobeNewswire)
May-22-24 04:01PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-20-24 08:00AM	Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-24 10:45AM	Standard BioTools Inc. (NASDAQ:LAB) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 08:59PM	LAB Stock Earnings: Standard BioTools Reported Results for Q1 2024 (InvestorPlace) -5.49% +7.59%
04:33PM	Standard BioTools: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 11:27AM	Standard BioTools Initiates Restructuring Plan With 10% Workforce Reduction (MT Newswires)
08:01AM	Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth (GlobeNewswire)
08:00AM	Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Apr-08-24 08:00AM	Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging (GlobeNewswire) +5.11%
Apr-03-24 04:01PM	Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan Platform for Translational Medicine Research (GlobeNewswire)
Mar-18-24 08:12AM	Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock (GlobeNewswire)
Mar-05-24 08:27AM	Standard BioTools Inc. (NASDAQ:LAB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 06:29AM	Q4 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) -5.06%
Feb-28-24 04:41PM	Standard BioTools Inc (LAB) Reports Growth and Margin Expansion in FY2023 Despite Economic ... (GuruFocus.com)
04:16PM	Standard BioTools: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-26-24 08:00AM	Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing (GlobeNewswire)
Feb-22-24 04:05PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-24 08:30AM	Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Feb-07-24 08:30AM	Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine (GlobeNewswire)
Jan-08-24 08:30AM	Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue (GlobeNewswire) +13.37%
Jan-05-24 08:46AM	Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools (GlobeNewswire)
Jan-04-24 10:23PM	Standard BioTools Stockholders Approve Merger with SomaLogic (GlobeNewswire) -5.39%
09:44PM	SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting (PR Newswire)
Dec-29-23 05:04PM	Glass Lewis Recommends Standard BioTools Stockholders Vote FOR All Proposals Relating to Proposed Merger with SomaLogic (GlobeNewswire)
Dec-28-23 04:16PM	Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools (PR Newswire) +5.45%
Dec-26-23 03:59PM	SomaLogic Issues Statement Correcting Madryn Asset Management's Misleading Disclosure (PR Newswire) +7.54%
Dec-22-23 06:57PM	ISS Recommends Standard BioTools Stockholders Vote FOR All Proposals Relating to Proposed Merger with SomaLogic (GlobeNewswire)
Dec-21-23 08:00AM	SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools (GlobeNewswire)
Dec-20-23 09:00AM	Skye Fund III Issues Letter Regarding Opposition to SomaLogic's Proposed Merger with Standard BioTools (GlobeNewswire) -8.10%
Dec-17-23 03:37PM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-12-23 04:32PM	SomaLogic Shareholder Madryn Opposes Standard BioTools Merger (Bloomberg)
Dec-11-23 10:37AM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-06-23 11:18AM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-04-23 08:00AM	Standard BioTools and SomaLogic Announce Date for Special Meetings of Stockholders to Vote on Proposed Merger (GlobeNewswire)
Nov-09-23 05:54AM	Q3 2023 Somalogic Inc Earnings Call (Thomson Reuters StreetEvents) +6.84%
Nov-08-23 12:47PM	Standard BioTools Inc. (NASDAQ:LAB) Q3 2023 Earnings Call Transcript (Insider Monkey)
06:52AM	Q3 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 04:23PM	Standard BioTools: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Standard BioTools Reports Third Quarter and Year-to-Date 2023 Financial Results (GlobeNewswire)
Nov-02-23 08:30AM	Standard BioTools to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-25-23 08:30AM	Standard BioTools Announces Conference Call and Webcast of Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire) -10.50%
Oct-10-23 10:22AM	Moore Kuehn Encourages VERY, PNT, LAB, and LVOX Investors to Contact Law Firm (GlobeNewswire)
Oct-05-23 02:42PM	Moore Kuehn Encourages APRN, FRGI, LAB, and CPRI Investors to Contact Law Firm (PR Newswire)
Oct-04-23 06:49PM	Why SomaLogic Stock Dived by 10% on Wednesday (Motley Fool) -22.22%
08:52AM	Standard BioTools to Combine with SomaLogic in $1 Billion Merger (Bloomberg)
08:00AM	Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools (GlobeNewswire)
Aug-09-23 09:06AM	Q2 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) +7.56%
Aug-08-23 05:36PM	Standard BioTools: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Standard BioTools Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-26-23 04:05PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-25-23 04:05PM	Standard BioTools Announces Conference Call and Webcast for Second Quarter 2023 Financial Results (GlobeNewswire)

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kim Hanjoon Alex	Chief Financial Officer	May 23 '25	Sale	0.94	1,428	1,344	930,286	May 28 05:54 PM
Mackay Sean	SVP & Chief Business Officer	May 23 '25	Sale	0.94	13,217	12,437	843,076	May 28 05:52 PM
Egholm Michael	President & CEO	May 23 '25	Sale	0.94	5,473	5,150	2,741,191	May 28 05:44 PM
Kim Hanjoon Alex	Chief Financial Officer	May 22 '25	Sale	1.00	1,355	1,358	931,714	May 27 08:33 PM
Egholm Michael	President & CEO	May 22 '25	Sale	1.00	5,116	5,126	2,746,664	May 27 08:28 PM
Mackay Sean	SVP & Chief Business Officer	May 21 '25	Sale	1.03	12,838	13,223	868,829	May 23 06:13 PM
Mackay Sean	SVP & Chief Business Officer	May 22 '25	Sale	1.00	12,536	12,561	856,293	May 23 06:13 PM
Mackay Sean	Officer	May 23 '25	Proposed Sale	0.94	13,217	12,441		May 23 04:19 PM
Kim Hanjoon Alex	Officer	May 23 '25	Proposed Sale	0.94	1,428	1,344		May 23 04:18 PM
Egholm Michael	Officer	May 23 '25	Proposed Sale	0.94	5,473	5,152		May 23 04:09 PM
Egholm Michael	President & CEO	May 21 '25	Sale	1.03	4,719	4,861	2,751,780	May 22 08:03 PM
Kim Hanjoon Alex	Chief Financial Officer	May 21 '25	Sale	1.03	1,407	1,449	933,069	May 22 08:01 PM
Egholm Michael	Officer	May 22 '25	Proposed Sale	1.00	5,116	5,126		May 22 04:20 PM
Mackay Sean	Officer	May 22 '25	Proposed Sale	1.00	12,536	12,560		May 22 04:13 PM
Kim Hanjoon Alex	Officer	May 22 '25	Proposed Sale	1.00	1,355	1,358		May 22 04:07 PM
Kim Hanjoon Alex	Officer	May 21 '25	Proposed Sale	1.03	1,407	1,451		May 21 04:22 PM
Mackay Sean	Officer	May 21 '25	Proposed Sale	1.03	12,838	13,240		May 21 04:16 PM
Egholm Michael	Officer	May 21 '25	Proposed Sale	1.03	4,719	4,867		May 21 04:13 PM
Egholm Michael	President & CEO	Apr 04 '25	Option Exercise	0.00	196,512	0	2,832,518	Apr 08 04:04 PM
Kim Hanjoon Alex	Chief Financial Officer	Apr 04 '25	Option Exercise	0.00	70,183	0	962,281	Apr 08 04:03 PM
Casdin Partners Master Fund, L	Director	Feb 28 '25	Buy	1.06	4,820,959	5,134,321	58,846,780	Mar 04 08:19 PM
Black Jeffrey G.	Former Officer	Nov 12 '24	Proposed Sale	2.12	57,971	123,098		Nov 12 04:13 PM
Taich Adam	Former Officer	Sep 09 '24	Proposed Sale	2.00	45,851	91,725		Sep 09 03:19 PM
Casdin Partners Master Fund, L	Director	Aug 27 '24	Buy	2.19	250,000	546,750	54,025,821	Aug 29 08:30 PM
Casdin Partners Master Fund, L	Director	Aug 23 '24	Buy	2.13	292,100	620,975	53,625,821	Aug 26 08:10 PM
Casdin Partners Master Fund, L	Director	Aug 22 '24	Buy	1.96	307,900	602,807	53,333,721	Aug 26 08:10 PM
Casdin Partners Master Fund, L	Director	Aug 26 '24	Buy	2.15	150,000	322,455	53,775,821	Aug 26 08:10 PM
Casdin Partners Master Fund, L	Director	Aug 21 '24	Buy	1.90	500,000	951,950	53,025,821	Aug 21 08:47 PM
Casdin Partners Master Fund, L	Director	Aug 20 '24	Buy	1.87	500,000	936,700	52,525,821	Aug 21 08:47 PM
Casdin Partners Master Fund, L	Director	Aug 19 '24	Buy	1.85	250,000	463,225	52,025,821	Aug 21 08:47 PM
Black Jeffrey G.	SVP & Chief Financial Officer	Aug 15 '24	Option Exercise	0.00	13,157	0	432,993	Aug 19 05:30 PM
Casdin Partners Master Fund, L	Director	Aug 14 '24	Buy	1.59	1,200,000	1,913,520	51,775,821	Aug 16 07:52 PM
Casdin Partners Master Fund, L	Director	Aug 13 '24	Buy	1.62	550,000	890,560	50,575,821	Aug 13 08:15 PM
Casdin Partners Master Fund, L	Director	Aug 09 '24	Buy	1.61	525,408	848,481	49,525,821	Aug 13 08:15 PM
Casdin Partners Master Fund, L	Director	Aug 12 '24	Buy	1.64	500,000	820,600	50,025,821	Aug 13 08:15 PM
Casdin Partners Master Fund, L	Director	Aug 08 '24	Buy	1.64	569,562	932,601	49,000,413	Aug 09 09:34 PM
Casdin Partners Master Fund, L	Director	Aug 07 '24	Buy	1.57	500,000	786,200	48,430,821	Aug 09 09:34 PM
Casdin Partners Master Fund, L	Director	Aug 02 '24	Buy	1.63	1,000,000	1,631,900	47,730,821	Aug 06 09:58 PM
Casdin Partners Master Fund, L	Director	Aug 05 '24	Buy	1.58	200,000	316,780	47,930,821	Aug 06 09:58 PM

Dollar change -0.74
Percentage change -3.24	%

BLFS Biolife Solutions Inc daily Stock Chart

Peers: CRSP CYRX NTLA BIO BMRN FATE NARI ASTE VIVS KPTI

| Held by: IJR VTI IWM VXF IWO IJT SPSM SLYG SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-0.04	Insider Own	4.07%	Shs Outstand	47.55M	Perf Week	2.84%
Market Cap	1.05B	Forward P/E	254.49	EPS next Y	0.09	Insider Trans	-37.26%	Shs Float	45.63M	Perf Month	0.32%
Enterprise Value	989.47M	PEG	-	EPS next Q	-0.03	Inst Own	99.15%	Short Float	9.55%	Perf Quarter	-1.52%
Income	-1.51M	P/S	9.96	EPS this Y	67.53%	Inst Trans	0.32%	Short Ratio	6.96	Perf Half Y	-14.87%
Sales	105.55M	P/B	2.98	EPS next Y	206.98%	ROA	-2.84%	Short Interest	4.36M	Perf YTD	-14.87%
Book/sh	7.42	P/C	11.87	EPS next 5Y	-	ROE	-3.29%	52W High	29.55 -25.20%	Perf Year	9.24%
Cash/sh	1.86	P/FCF	90.69	EPS past 3/5Y	-50.12% -55.83%	ROIC	-0.41%	52W Low	18.70 18.18%	Perf 3Y	51.79%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-11.62% 24.62%	Gross Margin	54.95%	Volatility	4.73% 4.75%	Perf 5Y	44.44%
Dividend TTM	-	EV/Sales	9.37	EPS Y/Y TTM	97.46%	Oper. Margin	-7.28%	ATR (14)	1.04	Perf 10Y	988.67%
Dividend Ex-Date	-	Quick Ratio	3.74	Sales Y/Y TTM	-23.12%	Profit Margin	-1.44%	RSI (14)	49.27	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.73	EPS Q/Q	95.78%	SMA20	-0.83%	Beta	1.77	Target Price	31.22
Payout	-	Debt/Eq	0.08	Sales Q/Q	-24.54%	SMA50	-2.43%	Rel Volume	0.52	Prev Close	22.84
Employees	159	LT Debt/Eq	0.04	Earnings	May 08 AMC	SMA200	-9.89%	Avg Volume	625.87K	Price	22.10
IPO	Nov 22, 1989	Option/Short	Yes / Yes	EPS/Sales Surpr.	79.42% 7.74%	Trades		Volume	245,288	Change	-3.24%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-30-24	Initiated	H.C. Wainwright	Buy	$29
Apr-04-24	Initiated	Jefferies	Buy	$22
Jul-11-23	Initiated	Craig Hallum	Buy	$29
Apr-25-22	Upgrade	Oppenheimer	Perform → Outperform	$28
Oct-19-21	Initiated	B. Riley Securities	Buy	$61
Oct-15-21	Resumed	Cowen	Outperform	$64
May-14-21	Downgrade	The Benchmark Company	Buy → Hold
Mar-23-21	Upgrade	The Benchmark Company	Hold → Buy	$54
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$40
Sep-22-20	Downgrade	Oppenheimer	Outperform → Perform
Sep-18-20	Initiated	Cowen	Outperform	$33
Aug-11-20	Downgrade	The Benchmark Company	Buy → Hold
Jul-08-20	Reiterated	Maxim Group	Buy	$18 → $26
Feb-24-20	Initiated	Lake Street	Buy	$25
Feb-19-20	Initiated	The Benchmark Company	Buy	$24
Feb-06-20	Resumed	B. Riley FBR	Buy	$27
Jan-08-20	Initiated	Stephens	Overweight	$23
Nov-21-19	Initiated	Oppenheimer	Outperform	$22
Jul-22-19	Initiated	H.C. Wainwright	Buy	$23
Nov-10-17	Reiterated	Maxim Group	Buy	$7 → $8

Show Previous Ratings

Jul-03-25 01:51PM	Ensign Group Boosts U.S. Presence With Idaho and Texas Facility Buyouts (Zacks)
Jun-20-25 06:48PM	E2open Parent, Mission Produce See Activist Action (Barrons.com)
Jun-19-25 01:03PM	Encompass Health Plans a 50-Bed Unit to Better Serve North Las Vegas (Zacks)
Jun-05-25 09:55AM	How Much Upside is Left in BioLife Solutions (BLFS)? Wall Street Analysts Think 41.72% (Zacks)
May-28-25 02:16PM	H.C. Wainwright Maintains Buy rating on BioLife (BLFS) Stock (Insider Monkey)
01:22PM	Loading…
May-21-25 01:22PM	EHC Opens Rehabilitation Unit in Fort Myers, Boosts Florida Footprint (Zacks)
05:26AM	Merit Medical acquires haemostatic device manufacturer Biolife for $120m (Medical Device Network)
May-14-25 08:03AM	BioLife Solutions to Participate in Upcoming Investor Conferences in May and June 2025 (PR Newswire)
May-13-25 09:55AM	Can BioLife Solutions (BLFS) Climb 30.68% to Reach the Level Wall Street Analysts Expect? (Zacks)
May-09-25 03:38AM	BioLife Solutions Inc (BLFS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
May-08-25 05:25PM	BioLife Solutions, Inc. (BLFS) Q1 Earnings and Revenues Beat Estimates (Zacks)
04:32PM	BioLife Solutions Updates Earnings Call Information (PR Newswire)
04:03PM	BioLife Solutions Reports First Quarter 2025 Financial Results (PR Newswire)
May-07-25 05:45PM	Green Thumb Industries Inc. (GTBIF) Q1 Earnings and Revenues Miss Estimates (Zacks)
05:20PM	BioLife Solutions Q1 2025 Earnings Preview (Seeking Alpha)
10:23AM	Loading…
10:23AM	What To Expect From BioLife Solutions Inc (BLFS) Q1 2025 Earnings (GuruFocus.com)
Apr-30-25 08:03AM	BioLife Solutions to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025 (PR Newswire)
Apr-23-25 05:15PM	ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates (Zacks) +11.24%
Apr-10-25 05:17AM	Strength Seen in Insulet (PODD): Can Its 7.2% Jump Turn into More Strength? (Zacks) -7.90%
Apr-07-25 08:03AM	BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company (PR Newswire) +5.08%
Apr-06-25 09:00AM	BioLife Solutions Stock: Back On Track, But Still Expensive (Seeking Alpha)
04:43AM	BioLife Solutions: A Steady Stock Lined Up For Success In A Booming Industry (Seeking Alpha)
Mar-24-25 07:27AM	5 Low-Leverage Stocks to Buy Amid Trump's Tariff Woes (Zacks) +5.68%
Mar-18-25 08:30AM	BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair (PR Newswire)
Mar-04-25 02:00AM	BioLife Solutions Inc (BLFS) Q4 2024 Earnings Call Highlights: Strong Margin Growth and ... (GuruFocus.com)
Mar-03-25 11:43PM	Q4 2024 BioLife Solutions Inc Earnings Call (Thomson Reuters StreetEvents)
08:10AM	BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	BioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-28-25 07:10AM	What To Expect From BioLife Solutions Inc (BLFS) Q4 2024 Earnings (GuruFocus.com)
Feb-20-25 04:03PM	BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025 (PR Newswire)
09:15AM	Loading…
Jan-29-25 09:15AM	BioLife Solutions, Inc. (BLFS) Hit a 52 Week High, Can the Run Continue? (Zacks)
Jan-24-25 09:40AM	Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-22-25 08:50AM	BioLife Solutions (BLFS) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jan-13-25 08:30AM	BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2024 Unaudited Revenue from Continuing Operations (PR Newswire)
Dec-16-24 08:11AM	BioLife Solutions Appoints Tony J. Hunt to its Board of Directors (PR Newswire)
Nov-14-24 04:05PM	BioLife Solutions Announces $6.1 million Sale of its Custom Biogenic Systems Freezer Subsidiary (PR Newswire) -10.20%
Nov-13-24 02:16AM	BioLife Solutions Inc (BLFS) Q3 2024 Earnings Call Highlights: Strategic Divestitures and ... (GuruFocus.com) -9.02%
Nov-12-24 05:45PM	BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	BioLife Solutions Reports Third Quarter 2024 Financial Results (PR Newswire)
08:05AM	BioLife Solutions Announces $73 Million Sale of its SciSafe Biostorage Subsidiary (PR Newswire)
Nov-11-24 07:11AM	What To Expect From BioLife Solutions Inc (BLFS) Q3 2024 Earnings (GuruFocus.com)
Oct-31-24 04:03PM	BioLife Solutions to Report Third Quarter 2024 Financial Results and Business Update on November 12, 2024 (PR Newswire)
Oct-21-24 09:40AM	Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year? (Zacks)
Oct-09-24 05:55PM	BioLife Solutions Inc (BLFS) Q2 2024 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com) -5.13%
Oct-07-24 08:50AM	Here's Why Momentum in BioLife Solutions (BLFS) Should Keep going (Zacks)
Sep-30-24 09:41AM	Disney upgraded, JPMorgan downgraded: Wall Street's top analyst calls (The Fly)
Sep-17-24 09:40AM	Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year? (Zacks) -7.89%
Aug-19-24 02:05AM	BioLife Solutions (BLFS) Surpassed Revenue and Earnings-Per-Share Expectations in Q2 (Insider Monkey)
Aug-08-24 09:58PM	BLFS Stock Earnings: BioLife Solns Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +11.04%
05:45PM	BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:03PM	BioLife Solutions Reports Second Quarter 2024 Financial Results (PR Newswire)
Aug-06-24 03:56PM	Is BioLife Solutions, Inc. (BLFS) the Best Organ Transplant and Diagnosis Stock to Buy Now? (Insider Monkey)
Jul-25-24 04:03PM	BioLife Solutions to Report Second Quarter 2024 Financial Results and Business Update on August 8, 2024 (PR Newswire)
Jul-12-24 08:50AM	What Makes BioLife Solutions (BLFS) a Good Fit for 'Trend Investing' (Zacks)
Jun-18-24 07:00PM	Insider Sale: Todd Berard Sells 10,000 Shares of BioLife Solutions Inc (BLFS) (GuruFocus.com)
May-31-24 11:17AM	BioLife (BLFS) Progresses in Cell & Gene Therapy With CryoCase (Zacks)
May-29-24 08:04AM	BioLife Solutions Introduces the CellSeal CryoCase at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver (PR Newswire)
May-18-24 02:34AM	Insider Sale: Chief Marketing Officer Todd Berard Sells 10,000 Shares of BioLife Solutions Inc ... (GuruFocus.com)
May-13-24 07:08AM	Benchmark Upgrades BioLife Solutions to Buy From Hold With $25 Price Target (MT Newswires) +5.73%
May-10-24 12:37PM	BioLife Solutions, Inc. (NASDAQ:BLFS) Q1 2024 Earnings Call Transcript (Insider Monkey) +8.50%
May-09-24 10:57PM	BLFS Stock Earnings: BioLife Solns Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:05PM	BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:03PM	BioLife Solutions Reports First Quarter 2024 Financial Results (PR Newswire)
May-02-24 10:01AM	BioLife Solutions, Inc. (BLFS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-30-24 04:12PM	BioLife Solutions to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024 (PR Newswire)
Apr-18-24 11:00AM	Insider Sell: Chief Marketing Officer Todd Berard Sells 10,000 Shares of BioLife Solutions Inc ... (GuruFocus.com)
08:05AM	BioLife Solutions Announces the Divestiture of its Stirling Freezer Business (PR Newswire)
Mar-27-24 04:37PM	Corporate Insiders Are Selling These 10 Small-Cap Stocks (Insider Monkey)
Mar-14-24 02:15AM	Director Amy Duross Sells 11,200 Shares of BioLife Solutions Inc (BLFS) (GuruFocus.com)
Mar-13-24 01:50AM	Insider Sell: Chief Marketing Officer Todd Berard Sells 7,508 Shares of BioLife Solutions Inc (BLFS) (GuruFocus.com) +5.77%
Mar-04-24 08:03AM	BioLife Solutions to Present at TD Cowen and Key Bank Investor Conferences (PR Newswire)
Mar-02-24 08:16AM	BioLife Solutions, Inc. (NASDAQ:BLFS) Q4 2024 Earnings Call Transcript (Insider Monkey)
Mar-01-24 06:02AM	Q4 2023 BioLife Solutions Inc Earnings Call (Thomson Reuters StreetEvents) +6.33%
Feb-29-24 04:03PM	BioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Feb-20-24 08:03AM	BioLife Solutions to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update on February 29, 2024 (PR Newswire)
Jan-08-24 08:15AM	BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue (PR Newswire) +10.16%
Nov-16-23 02:54AM	BioLife Solutions (BLFS) was Impacted by Inventory Destocking and Elongated Sales Cycles (Insider Monkey)
Nov-10-23 02:33PM	BioLife Solutions, Inc. (NASDAQ:BLFS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:04PM	BioLife Solutions Reports Third Quarter 2023 Financial Results (PR Newswire)
Nov-02-23 04:03PM	BioLife Solutions to Provide Third Quarter 2023 Financial Results and Business Update on November 9, 2023 (PR Newswire) +8.02%
12:27AM	Former CEO Michael Rice Sells 72,603 Shares of BioLife Solutions Inc (GuruFocus.com)
Oct-19-23 05:04PM	BioLife Solutions Announces Leadership Transitions & Preliminary Third Quarter Revenue with Updated Outlook for 2023 (PR Newswire) -8.85%
Oct-09-23 04:24AM	New Strong Sell Stocks for October 9th (Zacks)
Sep-13-23 07:47AM	New Strong Sell Stocks for September 13th (Zacks)
Aug-11-23 04:06PM	Why Shares of BioLife Solutions Plummeted This Week (Motley Fool)
06:05AM	Some BioLife Solutions, Inc. (NASDAQ:BLFS) Analysts Just Made A Major Cut To Next Year's Estimates (Simply Wall St.)
Aug-09-23 01:38PM	Why Shares of BioLife Solutions Are Slumping on Wednesday (Motley Fool) -28.71%
Aug-08-23 06:30PM	BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:03PM	BioLife Solutions Reports Second Quarter 2023 Financial Results, Updates Full Year 2023 Guidance and Provides Pro Forma First Half 2023 Financial Profile Excluding Freezer Business (PR Newswire)
Jul-27-23 04:03PM	BioLife Solutions to Provide Second Quarter 2023 Financial Results and Business Update on August 8, 2023 (PR Newswire)
Jul-26-23 01:30PM	Northland Capital Markets Institutional Investor Conference (ACCESSWIRE)
Jun-21-23 08:00PM	BLFS: What does Argus have to say about BLFS? (Argus Research)
Jun-14-23 08:03AM	BioLife Solutions Receives College of American Pathologists CAP-BAP Accreditation for All SciSafe® U.S. Biostorage Facilities (PR Newswire)
Jun-06-23 08:03AM	BioLife Solutions Launches the IntelliRate i67C Liquid Nitrogen (LN2) Controlled-Rate Freezer (PR Newswire)
May-12-23 07:45AM	We Think BioLife Solutions (NASDAQ:BLFS) Can Easily Afford To Drive Business Growth (Simply Wall St.)
May-11-23 07:34AM	Q1 2023 BioLife Solutions Inc Earnings Call (Thomson Reuters StreetEvents)
May-10-23 05:35PM	BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:03PM	BioLife Solutions Reports First Quarter 2023 Financial Results (PR Newswire)
May-02-23 04:03PM	BioLife Solutions to Provide First Quarter 2023 Financial Results and Business Update on May 10, 2023 (PR Newswire) -5.03%
Apr-26-23 08:00PM	BLFS: Lowering target price to $14.00 (Argus Research)

BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Aebersold Sarah	Chief Human Resources Officer	Jun 16 '25	Sale	22.23	711	15,806	78,721	Jun 18 05:44 PM
SARAH AEBERSOLD	Officer	Jun 16 '25	Proposed Sale	22.03	711	15,663		Jun 16 04:22 PM
Casdin Partners Master Fund, L	10% Owner	Jun 10 '25	Sale	23.80	1,000,000	23,800,000	7,707,165	Jun 12 08:27 PM
Berard Todd	Chief Marketing Officer	Jun 10 '25	Sale	23.70	362	8,579	134,922	Jun 12 05:24 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Jun 10 '25	Sale	23.70	637	15,097	353,118	Jun 12 05:24 PM
Wichterman Troy	Chief Financial Officer	Jun 10 '25	Sale	23.70	1,042	24,695	186,685	Jun 12 05:24 PM
Werner Sean	Chief Technology Officer	Jun 10 '25	Sale	23.70	65	1,540	27,610	Jun 12 05:24 PM
Aebersold Sarah	Chief Human Resources Officer	Jun 10 '25	Sale	23.70	235	5,570	79,432	Jun 12 05:23 PM
Foster Karen A.	Chief Quality and Operations	Jun 10 '25	Sale	23.70	320	7,584	194,996	Jun 12 05:23 PM
Casdin Partners Master Fund, L	10% Owner	Jun 10 '25	Proposed Sale	23.91	1,000,000	23,910,000		Jun 10 09:32 PM
Foster Karen A.	Chief Quality and Operations	May 28 '25	Sale	22.46	251	5,637	195,316	May 30 06:09 PM
Aebersold Sarah	Chief Human Resources Officer	May 28 '25	Sale	22.46	217	4,874	79,667	May 30 06:09 PM
Berard Todd	Chief Marketing Officer	May 28 '25	Sale	22.46	348	7,816	135,284	May 30 06:06 PM
Mathew Aby J.	EVP & Chief Scientific Officer	May 28 '25	Sale	22.46	521	11,702	308,486	May 30 06:04 PM
Werner Sean	Chief Technology Officer	May 28 '25	Sale	22.46	109	2,448	27,675	May 30 05:57 PM
Wichterman Troy	Chief Financial Officer	May 28 '25	Sale	22.46	583	13,094	187,727	May 30 05:54 PM
Wichterman Troy	Chief Financial Officer	Apr 09 '25	Sale	20.11	932	18,743	188,310	Apr 11 05:49 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Apr 09 '25	Sale	20.11	569	11,443	309,007	Apr 11 05:49 PM
Aebersold Sarah	Chief Human Resources Officer	Apr 09 '25	Sale	20.11	210	4,223	79,884	Apr 11 05:49 PM
Berard Todd	Chief Marketing Officer	Apr 09 '25	Sale	20.11	324	6,516	135,632	Apr 11 05:49 PM
Foster Karen A.	Chief Quality and Operations	Apr 09 '25	Sale	20.11	286	5,751	195,567	Apr 11 05:49 PM
Aebersold Sarah	Chief Human Resources Officer	Apr 01 '25	Sale	22.66	5,771	130,771	80,094	Apr 03 05:48 PM
Berard Todd	Chief Marketing Officer	Apr 01 '25	Sale	22.66	8,902	201,719	135,956	Apr 03 05:48 PM
Wichterman Troy	Chief Financial Officer	Apr 01 '25	Sale	22.66	25,687	582,067	189,242	Apr 03 05:48 PM
Foster Karen A.	Chief Quality and Operations	Apr 01 '25	Sale	22.66	7,869	178,312	195,853	Apr 03 05:48 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Apr 01 '25	Sale	22.66	10,589	239,947	309,576	Apr 03 05:48 PM
DuRoss Amy	Director	Mar 14 '25	Sale	24.96	5,632	140,575	23,811	Mar 20 07:09 PM
Aebersold Sarah	Chief Human Resources Officer	Mar 14 '25	Sale	24.96	5,632	140,575	45,860	Mar 18 05:59 PM
Aebersold Sarah	Chief Human Resources Officer	Mar 17 '25	Sale	25.44	2,695	68,561	43,165	Mar 18 05:59 PM
SARAH AEBERSOLD	Officer	Mar 17 '25	Proposed Sale	25.00	2,695	67,375		Mar 17 04:27 PM
AMY DUROSS	Director	Mar 14 '25	Proposed Sale	25.06	5,632	141,138		Mar 14 04:25 PM
Berard Todd	Chief Marketing Officer	Mar 11 '25	Sale	25.00	1,577	39,425	104,961	Mar 13 05:26 PM
Aebersold Sarah	Chief Human Resources Officer	Mar 12 '25	Sale	26.34	7,324	192,914	51,492	Mar 13 05:26 PM
Aebersold Sarah	Chief Human Resources Officer	Mar 11 '25	Sale	25.00	1,091	27,275	58,816	Mar 13 05:26 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Mar 11 '25	Sale	25.00	1,597	39,925	260,601	Mar 13 05:26 PM
Foster Karen A.	Chief Quality and Operations	Mar 11 '25	Sale	25.00	1,331	33,275	154,912	Mar 13 05:26 PM
Wichterman Troy	Chief Financial Officer	Mar 11 '25	Sale	25.00	4,151	103,775	116,809	Mar 13 05:25 PM
SARAH AEBERSOLD	Officer	Mar 12 '25	Proposed Sale	26.62	7,324	194,965		Mar 12 04:23 PM
Werner Sean	Chief Technology Officer	Mar 03 '25	Sale	25.46	136	3,463	4,953	Mar 05 05:14 PM
Werner Sean	Chief Technology Officer	Mar 04 '25	Sale	24.03	88	2,115	4,865	Mar 05 05:14 PM
Foster Karen A.	Chief Quality and Operations	Mar 03 '25	Sale	25.46	324	8,249	156,243	Mar 05 05:13 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Mar 03 '25	Sale	25.46	425	10,820	262,198	Mar 05 05:13 PM
Wichterman Troy	Chief Financial Officer	Mar 03 '25	Sale	25.46	660	16,804	120,960	Mar 05 05:13 PM
Aebersold Sarah	Chief Human Resources Officer	Mar 03 '25	Sale	25.46	284	7,231	59,907	Mar 05 05:13 PM
Berard Todd	Chief Marketing Officer	Mar 03 '25	Sale	25.46	424	10,795	106,538	Mar 05 05:13 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Feb 12 '25	Sale	26.54	92	2,442	262,623	Feb 14 05:47 PM
Wichterman Troy	Chief Financial Officer	Feb 12 '25	Sale	26.54	159	4,220	121,620	Feb 14 05:47 PM
Foster Karen A.	Chief Quality and Operations	Feb 12 '25	Sale	26.54	78	2,070	156,567	Feb 14 05:46 PM
Berard Todd	Chief Marketing Officer	Feb 12 '25	Sale	26.54	102	2,707	106,962	Feb 14 05:46 PM
Aebersold Sarah	Chief Human Resources Officer	Feb 12 '25	Sale	26.54	53	1,407	60,191	Feb 14 05:46 PM
Aebersold Sarah	Chief Human Resources Officer	Jan 06 '25	Sale	27.02	240	6,485	60,244	Jan 08 07:11 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Jan 06 '25	Sale	27.02	404	10,916	262,715	Jan 08 07:11 PM
Berard Todd	Chief Marketing Officer	Jan 06 '25	Sale	27.02	343	9,268	107,064	Jan 08 07:10 PM
DE GREEF RODERICK	President and CEO	Oct 31 '24	Sale	23.43	46,896	1,098,773	414,958	Jan 08 07:10 PM
Foster Karen A.	Chief Quality and Operations	Jan 06 '25	Sale	27.02	328	8,863	156,645	Jan 08 07:10 PM
Wichterman Troy	Chief Financial Officer	Jan 06 '25	Sale	27.02	987	26,669	121,779	Jan 08 07:10 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Dec 17 '24	Sale	27.16	13,196	358,403	263,119	Dec 19 05:19 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Dec 16 '24	Sale	27.33	7,604	207,817	276,315	Dec 19 05:19 PM
Wichterman Troy	Chief Financial Officer	Nov 26 '24	Sale	27.20	581	15,803	122,766	Nov 29 05:30 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Nov 26 '24	Sale	27.20	523	14,226	283,919	Nov 29 05:30 PM
Berard Todd	Chief Marketing Officer	Nov 26 '24	Sale	27.20	349	9,493	107,407	Nov 29 05:29 PM
Aebersold Sarah	Chief Human Resources Officer	Nov 26 '24	Sale	27.20	216	5,875	60,484	Nov 29 05:29 PM
Foster Karen A.	Chief Quality and Operations	Nov 26 '24	Sale	27.20	252	6,854	156,973	Nov 29 05:29 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Nov 15 '24	Option Exercise	2.06	10,000	20,600	327,046	Nov 19 05:32 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Nov 15 '24	Sale	21.17	25,000	529,150	302,046	Nov 19 05:32 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Nov 18 '24	Sale	20.05	17,604	352,960	284,442	Nov 19 05:32 PM
Berard Todd	Chief Marketing Officer	Nov 12 '24	Sale	26.34	91	2,397	107,756	Nov 14 06:38 PM
Foster Karen A.	Chief Quality and Operations	Nov 12 '24	Sale	26.34	66	1,738	157,225	Nov 14 06:38 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Nov 12 '24	Sale	26.34	123	3,240	317,046	Nov 14 06:37 PM
Wichterman Troy	Chief Financial Officer	Nov 12 '24	Sale	26.19	147	3,850	123,347	Nov 14 06:37 PM
Aebersold Sarah	Chief Human Resources Officer	Oct 30 '24	Sale	23.15	203	4,699	60,700	Nov 01 07:02 PM
Berard Todd	Chief Marketing Officer	Oct 30 '24	Sale	23.15	311	7,200	107,847	Nov 01 07:01 PM
Foster Karen A.	Chief Quality and Operations	Oct 30 '24	Sale	23.15	277	6,413	157,291	Nov 01 07:01 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Oct 30 '24	Sale	23.15	547	12,663	317,169	Nov 01 07:01 PM
Wichterman Troy	Chief Financial Officer	Oct 30 '24	Sale	23.15	894	20,696	123,494	Nov 01 07:01 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Oct 15 '24	Option Exercise	2.06	10,000	20,600	327,716	Oct 17 06:25 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Oct 16 '24	Option Exercise	2.06	10,000	20,600	327,716	Oct 17 06:25 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Oct 15 '24	Sale	23.28	10,000	232,800	317,716	Oct 17 06:25 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Oct 16 '24	Sale	23.17	10,000	231,700	317,716	Oct 17 06:25 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Sep 18 '24	Option Exercise	2.06	10,000	20,600	327,716	Sep 20 05:36 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Sep 19 '24	Option Exercise	2.06	10,000	20,600	327,716	Sep 20 05:36 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Sep 19 '24	Sale	25.47	10,000	254,700	317,716	Sep 20 05:36 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Sep 18 '24	Sale	23.90	10,000	239,000	317,716	Sep 20 05:36 PM
Foster Karen A.	Chief Quality and Operations	Sep 16 '24	Sale	25.12	267	6,707	157,568	Sep 18 05:45 PM
Foster Karen A.	Chief Quality and Operations	Jul 18 '24	Sale	22.50	240	5,400	157,931	Sep 18 05:45 PM
Foster Karen A.	Chief Quality and Operations	Aug 21 '24	Sale	25.61	96	2,459	157,835	Sep 18 05:45 PM
Berard Todd	Chief Marketing Officer	Sep 16 '24	Sale	25.12	367	9,219	108,158	Sep 18 05:45 PM
Berard Todd	Chief Marketing Officer	Jul 11 '24	Sale	20.54	287	5,895	108,607	Sep 18 05:45 PM
Berard Todd	Chief Marketing Officer	Aug 21 '24	Sale	25.61	82	2,100	108,525	Sep 18 05:45 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Sep 16 '24	Sale	25.12	343	8,616	317,716	Sep 18 05:45 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Jul 11 '24	Sale	20.54	313	6,429	318,170	Sep 18 05:45 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Aug 21 '24	Sale	25.61	111	2,843	318,059	Sep 18 05:45 PM
Aebersold Sarah	Chief Human Resources Officer	Jul 19 '24	Sale	21.01	300	6,303	61,196	Sep 18 05:45 PM
Aebersold Sarah	Chief Human Resources Officer	Sep 16 '24	Sale	25.12	229	5,752	60,903	Sep 18 05:45 PM
Aebersold Sarah	Chief Human Resources Officer	Jul 11 '24	Sale	20.54	187	3,841	61,496	Sep 18 05:45 PM
Aebersold Sarah	Chief Human Resources Officer	Aug 21 '24	Sale	25.61	64	1,639	61,132	Sep 18 05:45 PM
Wichterman Troy	Chief Financial Officer	Jul 11 '24	Sale	20.54	828	17,007	125,141	Sep 18 05:44 PM
Wichterman Troy	Chief Financial Officer	Sep 16 '24	Sale	25.12	611	15,348	124,388	Sep 18 05:44 PM
Wichterman Troy	Chief Financial Officer	Aug 21 '24	Sale	25.61	142	3,637	124,999	Sep 18 05:44 PM
Richardson Garrie	Chief Revenue Officer	Sep 16 '24	Sale	25.12	3,070	77,118	114,773	Sep 18 05:44 PM

Open in Screener

MXCT

MaxCyte Inc

Jul 07 • 02:20PM ET

2.17

Dollar change -0.06
Percentage change -2.68	%

Healthcare • Medical Devices • USA • NASD

Peers: NTLA CRSP EDIT SGMO BEAM CRBU CDXS ABCL ALLO

| Held by: VTI IWM VXF IWN IBB VTWO VHT IWC DFAS AVSC

Index	RUT	P/E	-	EPS (ttm)	-0.40	Insider Own	8.14%	Shs Outstand	106.31M	Perf Week	-1.14%
Market Cap	231.24M	Forward P/E	-	EPS next Y	-0.34	Insider Trans	-0.18%	Shs Float	97.66M	Perf Month	-9.00%
Enterprise Value	111.79M	PEG	-	EPS next Q	-0.10	Inst Own	74.22%	Short Float	3.65%	Perf Quarter	-16.35%
Income	-41.79M	P/S	6.14	EPS this Y	8.54%	Inst Trans	3.74%	Short Ratio	3.80	Perf Half Y	-47.72%
Sales	37.68M	P/B	1.16	EPS next Y	3.29%	ROA	-17.13%	Short Interest	3.56M	Perf YTD	-47.72%
Book/sh	1.88	P/C	1.67	EPS next 5Y	9.79%	ROE	-19.63%	52W High	5.20 -58.17%	Perf Year	-41.53%
Cash/sh	1.30	P/FCF	-	EPS past 3/5Y	-22.97% -11.37%	ROIC	-19.26%	52W Low	2.00 8.75%	Perf 3Y	-54.88%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.45% 12.31%	Gross Margin	69.93%	Volatility	5.15% 6.02%	Perf 5Y	-
Dividend TTM	-	EV/Sales	2.97	EPS Y/Y TTM	-12.34%	Oper. Margin	-133.18%	ATR (14)	0.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.58	Sales Y/Y TTM	-14.48%	Profit Margin	-110.92%	RSI (14)	45.43	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	12.23	EPS Q/Q	-5.79%	SMA20	-1.28%	Beta	-	Target Price	7.07
Payout	-	Debt/Eq	0.09	Sales Q/Q	-8.39%	SMA50	-7.56%	Rel Volume	0.44	Prev Close	2.23
Employees	114	LT Debt/Eq	0.09	Earnings	May 07 AMC	SMA200	-35.77%	Avg Volume	936.96K	Price	2.17
IPO	Dec 05, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3.41% 13.44%	Trades		Volume	313,104	Change	-2.68%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Initiated	Craig Hallum	Buy	$7
Oct-15-21	Resumed	Cowen	Outperform
Aug-24-21	Initiated	William Blair	Outperform
Aug-24-21	Initiated	Wedbush	Outperform	$36
Aug-24-21	Initiated	Stifel	Buy	$18
Aug-24-21	Initiated	Stephens	Overweight	$19
Aug-24-21	Initiated	Cowen	Outperform
Aug-24-21	Initiated	BTIG Research	Buy	$22

Jul-01-25 01:00AM	PHC Announces Exclusive Distribution of MaxCyte® ExPERT Platform in Japan (Business Wire)
Jun-11-25 02:00AM	MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies (GlobeNewswire)
May-13-25 10:51AM	MaxCyte, Inc. (MXCT): A Bull Case Theory (Insider Monkey)
May-08-25 03:27AM	MaxCyte Inc (MXCT) Q1 2025 Earnings Call Highlights: Strong Revenue Alignment Amidst Growth ... (GuruFocus.com) -11.31%
May-07-25 06:30PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance (GlobeNewswire)
Apr-10-25 02:00AM	MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire) -7.51%
Apr-08-25 09:35AM	Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT) (Zacks) -5.67%
Apr-07-25 09:35AM	Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround (Zacks)
Apr-04-25 12:00PM	MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know (Zacks) -5.77%
Mar-12-25 03:07AM	MaxCyte Inc (MXCT) Q4 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges (GuruFocus.com) -8.36%
Mar-11-25 04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance (GlobeNewswire)
Feb-12-25 02:00AM	MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs (GlobeNewswire)
Feb-07-25 02:00AM	MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference (GlobeNewswire)
Jan-30-25 02:00AM	MaxCyte Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments (GlobeNewswire)
12:00PM	Loading…
Jan-15-25 12:00PM	All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy (Zacks)
Jan-13-25 03:05AM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) +11.59%
Dec-23-24 02:00AM	MaxCyte Announces Retirement of Board Member Art Mandell (GlobeNewswire)
Dec-09-24 02:00AM	MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance (GlobeNewswire) +15.83%
Nov-13-24 08:05AM	MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics (GlobeNewswire)
Nov-07-24 02:00PM	MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ... (GuruFocus.com) -10.82%
Nov-06-24 05:55PM	MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance (GlobeNewswire)
Oct-31-24 08:05AM	MaxCyte to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Oct-16-24 12:00PM	MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Oct-15-24 08:05AM	MaxCyte Appoints Cynthia Collins to its Board of Directors (GlobeNewswire)
Oct-11-24 08:05AM	MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-10-24 08:05AM	MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer (GlobeNewswire)
Oct-09-24 05:08PM	MaxCyte Inc (MXCT) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Core Challenges (GuruFocus.com) -5.41%
Sep-17-24 03:32AM	MaxCyte and Kamau Therapeutics sign platform license agreement (Pharmaceutical Technology)
02:00AM	Loading…
Sep-16-24 02:00AM	MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases (GlobeNewswire)
Sep-05-24 04:05PM	MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference (GlobeNewswire)
Aug-06-24 05:50PM	MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -8.31%
04:05PM	MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance (GlobeNewswire)
Jul-17-24 08:50AM	MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jul-09-24 04:05PM	MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jun-13-24 09:55AM	Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect? (Zacks)
08:50AM	Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why (Zacks)
Jun-11-24 01:30AM	Insider Buying: President and CEO Maher Masoud Acquires 100,000 Shares of MaxCyte Inc (MXCT) (GuruFocus.com) -5.65%
May-29-24 08:05AM	MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference (GlobeNewswire)
May-22-24 08:05AM	MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development (GlobeNewswire)
May-12-24 08:19AM	MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 02:39PM	MaxCyte Shares Rise Sharply After Q1 Results Beat (MT Newswires) +18.07%
06:35AM	Q1 2024 MaxCyte Inc Earnings Call (Thomson Reuters StreetEvents)
03:58AM	MaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ... (GuruFocus.com)
May-07-24 08:58PM	MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:45PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance (GlobeNewswire)
Apr-10-24 08:05AM	MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-02-24 08:05AM	MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) (GlobeNewswire)
Mar-14-24 08:15AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 08:17AM	11 Oversold Healthcare Stocks To Buy Right Now (Insider Monkey)
Mar-12-24 05:31PM	MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance (GlobeNewswire)
Mar-04-24 04:05PM	MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results (GlobeNewswire) -12.21%
Feb-09-24 08:05AM	MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-30-24 08:05AM	MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugens Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers (GlobeNewswire)
Jan-23-24 08:05AM	MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs (GlobeNewswire)
Jan-08-24 04:05PM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +13.73%
Jan-03-24 08:05AM	MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline (GlobeNewswire) -11.60%
Jan-02-24 02:00AM	MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director (GlobeNewswire) +6.38%
Dec-19-23 11:21AM	Hedge Funds Say These Penny Stocks Are Poised to Explode (Insider Monkey) +9.01%
Dec-11-23 04:05PM	MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023 (GlobeNewswire)
Dec-07-23 11:05AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 124,450 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)
Dec-02-23 09:04AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 25,550 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)
Nov-16-23 08:05AM	MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member (GlobeNewswire)
Nov-09-23 12:57PM	MaxCyte, Inc. (NASDAQ:MXCT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:05PM	MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance (GlobeNewswire)
Nov-06-23 04:05PM	MaxCyte to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Oct-05-23 12:59PM	Why Shares of MaxCyte Are Plummeting on Thursday (Motley Fool) -20.64%
08:47AM	Why Is MaxCyte (MXCT) Stock Down 21% Today? (InvestorPlace)
Oct-04-23 04:05PM	MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance (GlobeNewswire) +9.00%
Sep-06-23 08:05AM	MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing (GlobeNewswire)
Sep-05-23 08:05AM	MaxCyte to Participate in Baird Global Healthcare Conference (GlobeNewswire)
Aug-09-23 04:05PM	MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance (GlobeNewswire) -10.44%
Aug-01-23 08:05AM	MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients (GlobeNewswire)
Jul-13-23 08:05AM	MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023 (GlobeNewswire)
Jul-10-23 08:05AM	MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies (GlobeNewswire) +7.78%
Jul-08-23 04:54AM	MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 77% of the company (Simply Wall St.)
Jul-06-23 08:05AM	MaxCyte Signs Strategic Platform License with Lyell Immunopharma (GlobeNewswire)
Jun-01-23 04:05PM	MaxCyte to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.56%
May-30-23 08:18AM	Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth (Simply Wall St.)
May-14-23 03:11AM	Earnings Working Against MaxCyte, Inc.'s (LON:MXCT) Share Price Following 28% Dive (Simply Wall St.)
May-10-23 05:25PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -19.78%
04:05PM	MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance (GlobeNewswire)
May-04-23 08:05AM	MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform (GlobeNewswire)
Apr-28-23 05:03AM	MaxCyte, Inc. (LON:MXCT) insider upped their holding by 400% earlier this year (Simply Wall St.)
Apr-27-23 06:36PM	7 Small-Cap Biotech Stocks with Massive Potential (InvestorPlace)
Apr-12-23 04:05PM	MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023 (GlobeNewswire)
Apr-06-23 09:30AM	The three-year returns have been strong for MaxCyte (LON:MXCT) shareholders despite underlying losses increasing (Simply Wall St.)
Mar-27-23 04:05PM	MaxCyte Appoints Douglas Swirsky as Chief Financial Officer (GlobeNewswire)
Mar-18-23 02:06AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-17-23 01:33AM	MaxCyte Full Year 2022 Earnings: US$0.23 loss per share (vs US$0.21 loss in FY 2021) (Simply Wall St.)
Mar-15-23 04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) +6.43%
Mar-08-23 08:00AM	MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology (GlobeNewswire)
Mar-06-23 04:05PM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance (PR Newswire) -7.55%
Feb-22-23 06:37PM	7 Must-Buy Penny Stocks to Add to Your Portfolio in 2023 (InvestorPlace)
Feb-01-23 04:05PM	MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-29-23 03:03AM	A fantastic week for MaxCyte, Inc.'s (LON:MXCT) 70% institutional owners, one-year returns continue to impress (Simply Wall St.)
Jan-03-23 04:05PM	MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs (PR Newswire) -6.23%

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hemrajani Rekha	Director	Jun 25 '25	Proposed Sale	2.09	10,684	22,378		Jun 25 04:05 PM
Soleymannezhad Ali	Chief Commercial Officer	Mar 18 '25	Sale	3.18	1,211	3,850	59,439	Mar 20 06:49 PM
Sandoval David I.	GENERAL COUNSEL	Mar 18 '25	Sale	3.18	353	1,122	64,219	Mar 20 06:47 PM
Swirsky Douglas J	CHIEF FINANCIAL OFFICER	Mar 18 '25	Sale	3.18	6,939	22,061	111,811	Mar 20 06:08 PM
Johnston John Joseph	Director	Jan 27 '25	Option Exercise	2.93	3,000	8,796	144,950	Jan 29 04:13 PM
Johnston John Joseph	Director	Jan 27 '25	Sale	4.64	3,000	13,935	141,950	Jan 29 04:13 PM
Sandoval David I.	GENERAL COUNSEL	Jan 13 '25	Sale	4.54	4,466	20,272	41,447	Jan 14 04:03 PM
Johnston John Joseph	Director	Dec 26 '24	Option Exercise	2.93	3,000	8,796	144,950	Dec 30 04:15 PM
Johnston John Joseph	Director	Dec 26 '24	Sale	4.01	3,000	12,021	141,950	Dec 30 04:15 PM
Johnston John Joseph	Affiliate	Dec 26 '24	Proposed Sale	4.11	12,000	49,320		Dec 26 04:16 PM
Johnston John Joseph	Director	Dec 09 '24	Option Exercise	2.35	2,495	5,863	144,445	Dec 10 04:30 PM
Johnston John Joseph	Director	Dec 06 '24	Option Exercise	2.93	505	1,478	142,455	Dec 10 04:30 PM
Johnston John Joseph	Director	Dec 09 '24	Sale	3.79	2,495	9,459	141,950	Dec 10 04:30 PM
Johnston John Joseph	Director	Dec 06 '24	Sale	3.70	505	1,869	141,950	Dec 10 04:30 PM
Erck Stanley C	Director	Nov 01 '24	Option Exercise	0.04	47,689	1,908	316,807	Nov 05 04:25 PM
Erck Stanley C	Director	Nov 01 '24	Sale	3.72	47,689	177,403	269,118	Nov 05 04:25 PM
Johnston John Joseph	Director	Oct 28 '24	Option Exercise	2.93	3,000	8,778	144,950	Oct 30 04:15 PM
Johnston John Joseph	Director	Oct 28 '24	Sale	3.72	3,000	11,166	141,950	Oct 30 04:15 PM
Erck Stanley C	Director	Oct 01 '24	Option Exercise	0.04	26,082	1,043	295,200	Oct 02 05:03 PM
Erck Stanley C	Director	Oct 02 '24	Option Exercise	0.04	21,607	864	290,725	Oct 02 05:03 PM
Erck Stanley C	Director	Oct 01 '24	Sale	3.78	26,082	98,590	269,118	Oct 02 05:03 PM
Erck Stanley C	Director	Oct 02 '24	Sale	3.71	21,607	80,162	269,118	Oct 02 05:03 PM
Johnston John Joseph	Director	Sep 26 '24	Option Exercise	2.93	3,000	8,778	144,950	Sep 30 04:15 PM
Johnston John Joseph	Director	Sep 26 '24	Sale	3.82	3,000	11,460	141,950	Sep 30 04:15 PM
Johnston John Joseph	Affiliate	Sep 26 '24	Proposed Sale	3.81	9,000	34,290		Sep 26 04:11 PM
Erck Stanley C	Director	Sep 04 '24	Option Exercise	0.04	29,767	1,191	298,885	Sep 05 05:10 PM
Erck Stanley C	Director	Sep 03 '24	Option Exercise	0.04	17,922	717	287,040	Sep 05 05:10 PM
Erck Stanley C	Director	Sep 04 '24	Sale	3.97	29,767	118,175	269,118	Sep 05 05:10 PM
Erck Stanley C	Director	Sep 03 '24	Sale	4.10	17,922	73,480	269,118	Sep 05 05:10 PM
Erck Stanley C	Officer	Sep 03 '24	Proposed Sale	4.32	143,067	618,049		Sep 03 04:36 PM
Johnston John Joseph	Director	Aug 26 '24	Option Exercise	2.93	3,000	8,778	144,950	Aug 28 04:30 PM
Johnston John Joseph	Director	Aug 26 '24	Sale	4.28	3,000	12,840	141,950	Aug 28 04:30 PM
Ross Thomas M.	EVP, GLOBAL SALES	Aug 02 '24	Option Exercise	1.64	17,857	29,303	42,857	Aug 05 06:57 PM
Ross Thomas M.	EVP, GLOBAL SALES	Aug 01 '24	Option Exercise	1.64	15,476	25,396	40,476	Aug 05 06:57 PM
Ross Thomas M.	EVP, GLOBAL SALES	Aug 02 '24	Sale	4.36	17,857	77,874	25,000	Aug 05 06:57 PM
Ross Thomas M.	EVP, GLOBAL SALES	Aug 01 '24	Sale	4.54	15,476	70,261	25,000	Aug 05 06:57 PM
Johnston John Joseph	Director	Jul 26 '24	Option Exercise	2.93	3,000	8,778	144,950	Jul 30 04:39 PM
Johnston John Joseph	Director	Jul 26 '24	Sale	4.75	3,000	14,238	141,950	Jul 30 04:39 PM
Ross Thomas M.	EVP, GLOBAL SALES	Jul 08 '24	Option Exercise	1.64	19,802	32,495	44,802	Jul 10 04:15 PM
Ross Thomas M.	EVP, GLOBAL SALES	Jul 09 '24	Option Exercise	1.64	13,531	22,204	38,531	Jul 10 04:15 PM
Ross Thomas M.	EVP, GLOBAL SALES	Jul 08 '24	Sale	4.03	19,802	79,782	25,000	Jul 10 04:15 PM
Ross Thomas M.	EVP, GLOBAL SALES	Jul 09 '24	Sale	4.03	13,531	54,584	25,000	Jul 10 04:15 PM

LAB

Standard BioTools Inc

BLFS

Biolife Solutions Inc

MXCT

MaxCyte Inc

Upgrade your FINVIZ experience